"For decades, people with PNH have lived with debilitating symptoms, including the threat of blood clots and their complications," said Leonard Bell, MD, Chief Executive Officer of Alexion. "This publication reinforces the importance of our goal to ensure that every PNH patient who can benefit from Soliris will have access to it."
"Many PNH patients face not only devastating symptoms, but a sharply increased risk for developing life-threatening blood clots as a result of their disease," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "This news provides additional hope for patients struggling with PNH and the danger of PNH-related blood clots. We look forward to seeing the impact this new analysis has on treatment of patients with PNH."
The publication, titled "Effect of the complement inhibitor eculizumab
on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria,"
analyzed data from 195 patients studied in the Soliris Phase II and Phase
III trials, including the TRIUMPH and SHEPHERD studies. Patients were
enrolled in the United States, Europe, Australia and Canada and treated
with Soliris for up to 54 months. Soliris reduced hemolysis in all treated
patients and reduced thrombosis by 92 percent, with three events during
Soliris treatment compared to 39 events during the same period of time
prior to treatment (P<0.0001). The collection of thrombotic events was
defined prospectively by clinical trial protocols.
|SOURCE Alexion Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.